BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street

BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear Street analysts reiterated a Buy rating on BioNTech SE (NASDAQ:BNTX), buoyed by top-line results on one of the company’s experimental treatments.

BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street

Source:unsplash

Gotistobart is the company’s anti-CTLA4 therapy in second-line or later squamous non-small cell lung cancer (NSCLC), showing tremendous potential. Immediate data shows the therapy reduces death risk by 54% compared to standard chemotherapy. It also boasts a 63% survival rate versus 30% with chemotherapy.

Clear Street remains optimistic that Gotistobart will provide a chemotherapy-free alternative with extended survival benefits for NSCLC patients progressing on PD-L1 inhibitors. Likewise, the research believes the company’s oncology pipeline remains undervalued given its potential to be combined with in-house antibody-drug conjugates.

BioNTech SE is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases. It is widely recognized for creating the first approved mRNA-based drug, the Pfizer-BioNTech COVID-19 vaccine, sold under the brand name Comirnaty.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

This article is originally published at Insider Monkey.